3-deoxydihydronormorphine | 69663-73-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: 3-deoxydihydronormorphine
• 英文别名: 4,5α-epoxy-morphinan-6α-ol；(4R,4aR,7S,7aR,12bS)-1,2,3,4,4a,5,6,7,7a,13-decahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
• CAS: 69663-73-6
• 化学式: C₁₆H₁₉NO₂
• 分子量: 257.332
• InChiKey: NTUQLFBJRFRUIN-WYEAJDFLSA-N

物化性质

• 沸点：
  447.8±45.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-deoxydihydronormorphine 、 3-溴丙烯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-allyl-3-deoxydihydronormorphine
  参考文献：
  名称：

  Deoxymorphines: role of the phenolic hydroxyl in antinociception and opiate receptor interactions

  摘要：

  Several 3-deoxy opioids and 3,6-dideoxydihydromorphine was synthesized to ascertain the effect of the phenolic hydroxyl group on antinociceptive potency and receptor binding affinity. Catalytic reduction of the 3-tetrazolyl ether derivatives of dihydromorphine provided the entry into the 3-deoxydihydro series. The prototype, 3-deoxymorphine, was prepared by lithium aluminum hydride reduction of 3-deoxy-N-carbethoxymorphinone, obtained via its 7-(phenylseleno) derivative. 3-Deoxydihydromorphinone and 3,6-dideoxydihydromorphine were found to be about as potent as, or more potent than, morphine in standard antiociceptive assays. Each of them, however, was less potent than the comparable 3-hydroxy analogue, and their binding affinity to the opiate receptor was substantially decreased. The epoxy ring in 3.6-dideoxydihydromorphine was found to increase the antinociceptive potency of the compound.

  DOI：

  10.1021/jm00189a007
• 作为产物：
  描述：

  3-deoxy-7,8-dihydromorphine 在 盐酸 、 iron(III) chloride hexahydrate 、 铁粉 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 水 为溶剂， 反应 19.0h， 生成 3-deoxydihydronormorphine
  参考文献：
  名称：

  口服活性阿扑吗啡候选药物的早期工艺开发和放大

  摘要：

  新型阿扑吗啡帕金森氏症候选药物 (MCL-509) 的制造路线已从 mg 实验室规模发展到适用于 20-50 L 规模的规模。虽然无法改进合成顺序，但所有六个反应步骤都需要显着改进才能扩大规模。去除了有害和有毒的试剂以及有害的步骤；去除所有浓缩至干燥和层析纯化；隔离在操作上得到简化，工厂周期时间缩短。两对步骤（1 和 2；5 和 6）被成功地压缩，并且重新设想了步骤 3、4 和 5，以便所有三个步骤都用替代试剂进行了实质性的重新开发。现在完全依靠结晶分离，每个中间体的产率、纯度和颜色都有了很大的提高。所有六个工艺步骤都可以很容易地转移到中试工厂，在以每批次 20-50 L 的规模进行生产之前，只需要进行最少的调整工作。因此，制造活动基本上按预期进行，没有出现问题，同时材料产量增加了大约 10 倍，同时还实现了必要的质量改进。

  DOI：

  10.1021/acs.oprd.2c00297

文献信息

• An investigation of the N-demethylation of 3-deoxymorphine and the affinity of the alkylation products to μ, δ, and κ receptors
  作者：Csaba Csutoras、Ao Zhang、Jean M Bidlack、John L Neumeyer

  DOI：10.1016/j.bmc.2004.03.011

  日期：2004.5

  The N-demethylation of 3-deoxymorphine (1) was investigated using methyl chloroformate and hydrazine. 3-Deoxynormorphine (2) was obtained in 70% yield, and 3-deoxydihydronormorphine (3) was also obtained as a side product. The mu, delta, and kappa receptor binding affinity of a series of N-substituted 3-deoxynormorphines 6 and 7 and N-substituted 3-deoxydihydronormorphines 8-11 was also determined. (C) 2004 Elsevier Ltd. All rights reserved.
• US4440932A
  申请人：——

  公开号：US4440932A

  公开（公告）日：1984-04-03
• Deoxymorphines: role of the phenolic hydroxyl in antinociception and opiate receptor interactions
  作者：Juergen Reden、Marvin F. Reich、Kenner C. Rice、Arthur E. Jacobson、Arnold Brossi、Richard A. Streaty、Werner A. Klee

  DOI：10.1021/jm00189a007

  日期：1979.3

  Several 3-deoxy opioids and 3,6-dideoxydihydromorphine was synthesized to ascertain the effect of the phenolic hydroxyl group on antinociceptive potency and receptor binding affinity. Catalytic reduction of the 3-tetrazolyl ether derivatives of dihydromorphine provided the entry into the 3-deoxydihydro series. The prototype, 3-deoxymorphine, was prepared by lithium aluminum hydride reduction of 3-deoxy-N-carbethoxymorphinone, obtained via its 7-(phenylseleno) derivative. 3-Deoxydihydromorphinone and 3,6-dideoxydihydromorphine were found to be about as potent as, or more potent than, morphine in standard antiociceptive assays. Each of them, however, was less potent than the comparable 3-hydroxy analogue, and their binding affinity to the opiate receptor was substantially decreased. The epoxy ring in 3.6-dideoxydihydromorphine was found to increase the antinociceptive potency of the compound.
• Early Process Development and Scale-Up of Orally Active Apomorphine Drug Candidates
  作者：Ekaterina Y. Melikhova、Nolwenn Derrien、Nadia Fleary-Roberts、Siân M. Forsyth、Sofia Papadouli、Antonio M. Ruda、Vargini G. Thangavadivale、Simon N. G. Tyler、Jonathan D. Moseley

  DOI：10.1021/acs.oprd.2c00297

  日期：2023.1.20

  steps were substantially redeveloped with alternative reagents. Now relying solely on crystallizations for isolation, the yield, purity, and color of each intermediate was greatly improved. All six process steps were easily transferred to the pilot plant with only minimal accommodation work required prior to manufacture on a 20–50 L scale per batch. Thus, the manufacturing campaign performed essentially

  新型阿扑吗啡帕金森氏症候选药物 (MCL-509) 的制造路线已从 mg 实验室规模发展到适用于 20-50 L 规模的规模。虽然无法改进合成顺序，但所有六个反应步骤都需要显着改进才能扩大规模。去除了有害和有毒的试剂以及有害的步骤；去除所有浓缩至干燥和层析纯化；隔离在操作上得到简化，工厂周期时间缩短。两对步骤（1 和 2；5 和 6）被成功地压缩，并且重新设想了步骤 3、4 和 5，以便所有三个步骤都用替代试剂进行了实质性的重新开发。现在完全依靠结晶分离，每个中间体的产率、纯度和颜色都有了很大的提高。所有六个工艺步骤都可以很容易地转移到中试工厂，在以每批次 20-50 L 的规模进行生产之前，只需要进行最少的调整工作。因此，制造活动基本上按预期进行，没有出现问题，同时材料产量增加了大约 10 倍，同时还实现了必要的质量改进。